Flexion Therapeutics, Inc. (FLXN) financial statements (2021 and earlier)

Company profile

Business Address 10 MALL ROAD
BURLINGTON, MA 01803
State of Incorp. DE
Fiscal Year End December 31
SIC 2834 - Pharmaceutical Preparations (benchmarking)
More info Complete financial analysis Financial benchmarking

Balance sheet (Statement of financial position) ($ in millions)

12/31/2020
12/31/2019
12/31/2018
12/31/2017
12/31/2016
12/31/2015
12/31/2014
ASSETS
Current Assets
Cash, cash equivalents, and short-term investments, including:175137259424210119152
Cash and cash equivalents10882871283163103
Short-term investments685417226517548 
Other undisclosed cash, cash equivalents, and short-term investments000325749
Receivables303714110 
Inventory, net of allowances, customer advances and progress billings151782   
Inventory151782   
Prepaid expense4552100
Deferred costs      0
Other undisclosed current assets100(31)(3)(7)0
Total current assets:226196285398209112152
Noncurrent Assets
Operating lease, right-of-use asset78
Property, plant and equipment201411111271
Long-term investments and receivables   3257 
Long-term investments   3257 
Restricted cash and investments   1000
Deferred costs      0
Other noncurrent assets     00
Other undisclosed noncurrent assets      (0)
Total noncurrent assets:2622114317151
TOTAL ASSETS:252218296441226127153
LIABILITIES AND EQUITY
Liabilities
Current Liabilities
Accounts payable and accrued liabilities27352721886
Accounts payable715126242
Accrued liabilities20201414643
Employee-related liabilities      1
Interest and dividends payable      0
Deferred revenue10 
Debt17110109 2
Other undisclosed current liabilities2     (1)
Total current liabilities:553637311887
Noncurrent Liabilities
Long-term debt and lease obligation504841321152
Long-term debt, excluding current maturities444041321152
Operating lease, liability68
Liabilities, other than long-term debt0010000
Other liabilities0010000
Other undisclosed noncurrent liabilities163153145137   
Total noncurrent liabilities:21320114915022152
Total liabilities:26923818618139238
Stockholders' equity
Stockholders' equity attributable to parent(17)(20)110260187104145
Common stock0000000
Additional paid in capital766648629610399244238
Accumulated other comprehensive income (loss)(0)0(0)(0)(0)(0)(0)
Accumulated deficit(782)(669)(519)(349)(212)(140)(93)
Total stockholders' equity:(17)(20)110260187104145
TOTAL LIABILITIES AND EQUITY:252218296441226127153

Income statement (P&L) ($ in millions)

12/31/2020
12/31/2019
12/31/2018
12/31/2017
12/31/2016
12/31/2015
12/31/2014
Revenues8673230   
Revenue, net0   
Cost of revenue
(Cost of Goods and Services Sold)
(19)(10)(7)(0)   
Gross profit:6663150   
Operating expenses(159)(199)(174)(130)(70)(46)(27)
Operating loss:(93)(136)(159)(130)(70)(46)(27)
Nonoperating expense(20)(14)(10)(8)(2)(0)(0)
Investment income, nonoperating1354210
Other nonoperating income (expense)(1)01(0)(2)(1)(0)
Interest and debt expense(20)(0)(16)(11)(2)(1)(0)
Loss from continuing operations before equity method investments, income taxes:(133)(150)(185)(149)(74)(47)(28)
Other undisclosed income from continuing operations before income taxes20      
Loss from continuing operations before income taxes:(113)(150)(185)(149)(74)(47)(28)
Income tax expense(0)      
Loss before gain (loss) on sale of properties:(114)(150)(185)(149)(74)(47)(28)
Other undisclosed net income 016    
Net loss:(114)(150)(170)(149)(74)(47)(28)
Other undisclosed net income attributable to parent   11210
Net loss available to common stockholders, diluted:(114)(150)(170)(137)(72)(46)(27)

Comprehensive Income ($ in millions)

12/31/2020
12/31/2019
12/31/2018
12/31/2017
12/31/2016
12/31/2015
12/31/2014
Net loss:(114)(150)(170)(149)(74)(47)(28)
Other comprehensive income (loss)    0(0)(0)
Comprehensive loss:(114)(150)(170)(149)(74)(47)(28)
Other undisclosed comprehensive income (loss), net of tax, attributable to parent(0)0011210
Comprehensive loss, net of tax, attributable to parent:(114)(150)(169)(138)(72)(46)(27)

Statements sources

The financial statements are based on the company's filings with the The U.S. Securities and Exchange Commission (SEC) through the Electronic Data Gathering, Analysis, and Retrieval system (EDGAR). The information is derived from the 10-K and 10-Q reports submitted to the SEC in XBRL (eXtensible Business Reporting Language) format and presented according to the US GAAP Taxonomy. Please review the original filings for a more detailed information.

Login to ReadyRatios

 

Have you forgotten your password?

Are you a new user?

Login As
You can log in if you are registered at one of these services: